Longer-acting eye treatment could reduce vision loss for Indigenous Australians
Indigenous people in Australia experience three times more vision loss than non-Indigenous people, creating a concerning gap for vision.
Apr 19, 2022
0
2
Indigenous people in Australia experience three times more vision loss than non-Indigenous people, creating a concerning gap for vision.
Apr 19, 2022
0
2
The French competition authority (AFC) on Thursday slapped a record 444 million euro ($500 million) fine on pharma groups Novartis, Roche and Genentech over market abuses in sales of macular degeneration drugs.
Sep 9, 2020
0
3
Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently. ...
Apr 23, 2020
0
11
The simultaneous use of antibodies based on two differing mechanisms of action leads to a more effective destruction of tumors. This has been demonstrated by a study in animal models by medical oncologists and scientists ...
Dec 30, 2019
0
388
Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or ...
Oct 10, 2018
0
1
Children with incurable brain tumours could benefit from potentially life-extending treatment if genetic testing was used to personalise therapy as it is in many adults, major new research reports.
May 14, 2018
0
17
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.
Sep 15, 2017
0
2
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), ...
Feb 28, 2016
0
46
Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same ...
Aug 13, 2015
0
22
Breast cancer drugs such as Herceptin as well as new uses for multi-cancer drug Avastin helped Swiss pharmaceutical firm Roche grow sales by 3 percent during the first quarter.
Apr 22, 2015
0
4
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.
This text uses material from Wikipedia, licensed under CC BY-SA